Pre-treatment clinical features in central retinal vein occlusion that predict visual outcome following intravitreal ranibizumab

Table 2 Univariate analysis of predictors of poorer VA at 3 and 12 months after starting intravitreal ranibizumab in patients with CRVO

	3 months (P value)	12 months (P value)
Poorer baseline VA	< 0.001	0.007
Increasing age	< 0.001	< 0.001
Presence of CWS	0.004	0.045
Deep dark haemorrhages	0.362	0.535
Foveal detachment	0.463	0.728
Increasing CRT	0.143	0.056
Time from presentation to IVT	0.199	0.529
Number of injections	0.859	0.949

VA visual acuity, CRVO central retinal vein occlusion, CWS cotton wool spots, CRT central retinal thickness, IVT intravitreal therapy

ISSN: 1471-2415